Phaseline

Targets › CSF2RA

CSF2RA (Granulocyte-macrophage colony-stimulating factor receptor subunit alpha): drug programs, companies and trials

1 program from 1 company in 24 trials: 19 Phase 2, 5 Phase 1; Neurology, Oncology; next expected readout Apr 2028.

Low affinity receptor for granulocyte-macrophage colony-stimulating factor. Transduces a signal that results in the proliferation, differentiation, and functional activation of hematopoietic cells. (UniProt, P15509)

Open in Phaseline: the race on CSF2RA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Y-mAbs TherapeuticsSargramostim
Granulocyte-macrophage colony-stimulating factor receptor agonist
CSF2RA, CSF2RBPhase 2Neuroblastoma; Bilateral Breast Carcinoma; Neuroblastoma Recurrent; Alzheimer Disease …Apr 2028

Conditions

Neuroblastoma (2) Bilateral Breast Carcinoma (1) Neuroblastoma Recurrent (1) Alzheimer Disease (1) Solid Cancer (1) Transplant-Related Hematologic Malignancy (1) Cervical Cancer (1) Advanced Melanoma (1) Anatomic Stage IV Breast Cancer AJCC v8 (1) Oncology (1) Recurrent Osteosarcoma (1) Ganglioneuroblastoma, Nodular (1)

Modalities

antibody (1)

Companies

Y-mAbs Therapeutics (1)

Related targets

CSF2RB (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.